Product information and disease descriptionPlace of product in therapyDisease description
Burden of Neovascular age-related macular degeneration
12 evidence topics · 5 sources
Economic impact of diagnostic testing
Not applicable.
Lytenava (bevacizumab-vikg)
Neovascular age-related macular degeneration
- Manufacturer
- Outlook Therapeutics
- Regulatory submission
- BLA approved July 2026
- Last updated